Olink Holding AB (publ) is committed to certain values and a distinct corporate philosophy. The company prioritizes innovation, integrity, and collaboration in its operations. Olink Holding AB (publ) aims to consistently deliver groundbreaking solutions by fostering a culture of cutting-edge research and development. The company strongly believes in maintaining the highest ethical standards and maintaining transparency in all its dealings. With a focus on teamwork and partnerships, Olink Holding AB (publ) strives to create value for its stakeholders, including customers, employees, and investors. This commitment to excellence and dedication to its core values sets Olink Holding AB (publ) apart in the industry.

Olink Holding AB (publ) is primarily present in Sweden, where its headquarters are located. As a biotechnology company, it focuses on developing and providing innovative solutions for researchers and scientists in the field of proteomics. With its advanced technology and expertise, Olink Holding AB (publ) has gained recognition not only in Sweden but also on a global scale. Its products and services are widely utilized by customers in various countries and regions worldwide, allowing researchers worldwide to unravel the complexities of human biology.

Olink Holding AB (publ) has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) in 2020, raising substantial capital for future growth. Additionally, Olink Holding AB (publ) has expanded its product portfolio and launched innovative solutions in the field of proteomics, revolutionizing biomedical research. Furthermore, the company has established key collaborations with renowned academic institutions and pharmaceutical companies to advance the applications of its technologies. Olink Holding AB (publ) has also received recognition for its accomplishments, including being listed on Nasdaq Stockholm's main market. These achievements highlight Olink Holding AB (publ) as a forward-thinking company making notable strides in the field of proteomics.

Olink Holding AB (publ) is a renowned biotechnology company that specializes in innovative solutions for proteomics, enabling scientists to explore the full potential of proteins in research. Established in 2016, Olink has rapidly gained recognition for its cutting-edge technologies, such as proximity extension assays (PEA), which revolutionize protein biomarker discovery. With a robust foundation rooted in decades of scientific expertise from Uppsala University in Sweden, Olink has evolved into a global leader in precision proteomics. Olink's dedication to advancing scientific understanding and improving patient outcomes drives its mission to provide reliable and scalable solutions for protein biomarker analysis across various therapeutic fields, including oncology, inflammation, cardiovascular disease, and more.

The main competitors of Olink Holding AB (publ) in the market are companies like Thermo Fisher Scientific, Illumina Inc., and Bio-Techne Corporation.

Olink Holding AB (publ) is primarily active in the life sciences industry.

Olink Holding AB (publ) operates with a distinct business model. The company specializes in developing and providing highly advanced solutions for protein biomarker discovery and exploration. Olink's innovative technologies and products empower researchers with the ability to analyze proteins in complex biological systems with high precision and sensitivity. By offering a comprehensive suite of tools, services, and kits, Olink facilitates the understanding of disease mechanisms, identification of new drug targets, and supports personalized medicine research. The company's business model revolves around driving scientific advancements and enabling efficient protein analysis to enhance biomedical research and improve patient outcomes. Olink Holding AB (publ) is dedicated to delivering cutting-edge solutions for the global life science community.

Olink Holding AB (publ) KGV yra −171,60.

Olink Holding AB (publ) KUV yra 14,76.

AlleAktien kokybės įvertis Olink Holding AB (publ) yra 4/10.

tikėtina Olink Holding AB (publ) pardavimai yra 219,66 mln. USD.

tikėtina Olink Holding AB (publ) pelnas yra −18,90 mln. USD.

Olink Holding AB (publ) is a biotechnology company that provides advanced solutions for proteomics. The company was founded in 2004 and is headquartered in Uppsala, Sweden, with branches in the United States, United Kingdom, and China. Proteomics deals with the entirety of all proteins that occur within a cell, tissue, or organism. Proteins are important building blocks of life and play a crucial role in many biological processes. By analyzing proteins, important insights into the functioning of cells and organisms can be gained. Olink offers a comprehensive range of instruments, reagents, and services for proteomics. One of the company's key products is Proximity Extension Assay (PEA), a technology developed by Olink itself. PEA is a highly sensitive method that allows simultaneous measurement of hundreds of proteins in a single sample. Olink offers a wide range of PEA products for research, diagnostics, and drug development. The main application areas for Olink's products include cancer research, cardiovascular research, neurology, and immunology. In cancer research, Olink offers a special platform called Oncology III, which captures a large number of proteins related to cancer. This platform can help identify new biomarkers for cancer diagnostics and evaluate the effectiveness of cancer drugs. Another important application area for Olink's products is clinical studies. The company works closely with pharmaceutical and biotech companies to support their development programs. Olink's PEA technology can help identify biomarkers that can predict the effectiveness of drugs and the likelihood of side effects. Olink also offers a range of services, including customized PEA platforms for specific applications and sample analysis for customers. Olink's business model is based on developing and offering innovative technologies and solutions for proteomics. The company works closely with customers and partners to understand their needs and develop customized solutions. Olink has experienced strong growth so far and is currently expanding its global presence. Overall, Olink is a leading company in the field of proteomics and provides high-quality solutions for research, diagnostics, and drug development. With the development of new products and services and the continuation of collaboration with customers and partners, the company should continue to be successful in the future.

Olink Holding AB (publ) moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Olink Holding AB (publ) arba įmonė dividendų nemoka.

Olink Holding AB (publ) ISIN yra US6807101000.

Olink Holding AB (publ) WKN yra A2QRZ6.

Olink Holding AB (publ) akcijų simbolis yra OLK.

Per paskutinius 12 mėnesių Olink Holding AB (publ) išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Olink Holding AB (publ) tikėtina išmokės dividendus, kurie sudarys 0 USD.

Olink Holding AB (publ) šiuo metu yra dydžio dividendų grąža.

Olink Holding AB (publ) moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Olink Holding AB (publ) per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Olink Holding AB (publ) priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Olink Holding AB (publ) dividendą nuo 2024-08-10, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-08-10.

Paskutinės dividendų išmokėjimas įvyko 2024-08-10.

2023 metais Olink Holding AB (publ) išmokėjo 0 USD dividendų.

Olink Holding AB (publ) dividendai yra mokami USD.